Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 9/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10608800 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL7648748 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL10402701 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL6279249 | 0.89 | KDM4E (0.50) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL10401817 | 0.88 | KDM4E (0.56) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL10509997 | 0.87 | KDM4E (0.49) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL10510003 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL16774398 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL8882349 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL8881825 | 0.83 | KDM4E (0.48) | KDM4EALDH1A1MAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5663029-A | DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2037947-A2 | MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2007143694-A2 | MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| US-4968819-A | CATALYTIC SELECTIVE ETHERIFICATION | ALKALOIDA VEGYESZETI GYAR (HU) | 1990-11-06 | — | — | US | disclosed |
| US-4866089-A | 7-ALKOXY-8-METHOXY-2,2-DIMETHYL-2H-CHROMENES; INSECTICIDES, NEMATOCIDES | ALKALOIDA VEGYESZETI GYAR (HU) | 1989-09-12 | — | — | US | disclosed |
| EP-0271550-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES AND COMPOSITIONS CONTAINING THEM | ALKALOIDA VEGYéSZETI GYáR (HU) | 1988-06-22 | — | — | EP | disclosed |
| WO-1988000197-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES AND COMPOSITIONS CONTAINING THEM | ALKALOIDA VEGYE^´SZETI GYA^´R (HU) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | KDM4E 893/4885ALDH1A1 938/4885MAPT 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.